137 related articles for article (PubMed ID: 2379509)
1. A comparison of the usefulness of serum measurements of CA 125, CA 50 and TATI in patients with malignant and benign gynecological pathology.
Gadducci A; Ferdeghini M; Facchini V; Ceccarini T; Prontera C; Bianchi R; Fioretti P
Eur J Gynaecol Oncol; 1990; 11(2):111-5. PubMed ID: 2379509
[TBL] [Abstract][Full Text] [Related]
2. A comparative evaluation of the ability of serum CA 125, CA 19-9, CA 15-3, CA 50, CA 72-4 and TATI assays in reflecting the course of disease in patients with ovarian carcinoma.
Gadducci A; Ferdeghini M; Ceccarini T; Prontera C; Facchini V; Bianchi R; Fioretti P
Eur J Gynaecol Oncol; 1990; 11(2):127-33. PubMed ID: 2379512
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated trypsin inhibitor and cancer antigen 125 in pelvic masses.
Mogensen O; Mogensen B; Jakobsen A
Gynecol Oncol; 1990 Aug; 38(2):170-4. PubMed ID: 2167279
[TBL] [Abstract][Full Text] [Related]
4. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
5. Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.
Halila H; Lehtovirta P; Stenman UH
Br J Cancer; 1988 Mar; 57(3):304-7. PubMed ID: 3162682
[TBL] [Abstract][Full Text] [Related]
6. [Clinical evaluation of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological tumor].
Shigemasa K; Hiura M; Ioka A; Yokoyama T; Nogawa T; Chiba T
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Mar; 45(3):256-7. PubMed ID: 8492013
[No Abstract] [Full Text] [Related]
7. [Serum level of the tumor marker CA 125 in ovarian pathology].
Bagni B; Pansini FS; Feggi LM; Prandini N; Mollica G
Radiol Med; 1987 Nov; 74(5):448-50. PubMed ID: 3479814
[TBL] [Abstract][Full Text] [Related]
8. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis.
Gadducci A; Ferdeghini M; Prontera C; Moretti L; Mariani G; Bianchi R; Fioretti P
Gynecol Oncol; 1992 Feb; 44(2):147-54. PubMed ID: 1312052
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological diseases.
Torre GC; Rembado R; Barbetti V; Vigliercio GP; Foglia M; Calabrese A; Corongiu F
Scand J Clin Lab Invest Suppl; 1991; 207():15-8. PubMed ID: 1780684
[TBL] [Abstract][Full Text] [Related]
10. Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Rispoli G; Prontera C; Bianchi R; Fioretti P
Scand J Clin Lab Invest Suppl; 1991; 207():19-24. PubMed ID: 1780685
[TBL] [Abstract][Full Text] [Related]
11. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.
Einhorn N; Bast RC; Knapp RC; Tjernberg B; Zurawski VR
Obstet Gynecol; 1986 Mar; 67(3):414-6. PubMed ID: 2418395
[TBL] [Abstract][Full Text] [Related]
12. Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
Mogensen O; Mogensen B; Jakobsen A
Br J Cancer; 1990 Feb; 61(2):327-9. PubMed ID: 2310684
[TBL] [Abstract][Full Text] [Related]
13. TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.
Medl M; Ogris E; Peters-Engl C; Leodolter S
Br J Cancer; 1995 May; 71(5):1051-4. PubMed ID: 7734298
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of tumor-associated trypsin inhibitor (TATI) in women with benign and malignant gynecological disease.
Inaudi P; Petrilli S; De Leo V; Bernabei A; Pasqui L; D'Antona N
Scand J Clin Lab Invest Suppl; 1991; 207():11-3. PubMed ID: 1780683
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of the tumour-associated trypsin inhibitor in patients with endometriosis.
Medl M; Ogris E; Peters-Engl C; Mierau M; Buxbaum P; Leodolter S
Br J Obstet Gynaecol; 1997 Jan; 104(1):78-81. PubMed ID: 8988701
[TBL] [Abstract][Full Text] [Related]
16. Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids.
de Bruijn HW; ten Hoor KA; Boonstra H; Marrink J; Krans M; Aalders JG
Tumour Biol; 1993; 14(2):105-15. PubMed ID: 8392219
[TBL] [Abstract][Full Text] [Related]
17. Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA.
Halila H; Huhtala ML; Haglund C; Nordling S; Stenman UH
Br J Cancer; 1987 Aug; 56(2):153-6. PubMed ID: 3117086
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
Peters-Engl C; Medl M; Ogris E; Leodolter S
Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
[TBL] [Abstract][Full Text] [Related]
19. Effect of intracavitary radiotherapy on tumor-associated trypsin inhibitor (TATI) in patients with cervical and endometrial cancer.
Lehtovirta P; Turpeinen U; Stenman UH
Gynecol Oncol; 1990 Jul; 38(1):110-3. PubMed ID: 2354815
[TBL] [Abstract][Full Text] [Related]
20. Tumour-associated trypsin inhibitor, TATI. Clinical use and biological function.
Stenman UH; Koivunen E; Itkonen O; Turpeinen U; Halila H; Huhtala ML
Ann Chir Gynaecol; 1989; 78(1):77-82. PubMed ID: 2667452
[No Abstract] [Full Text] [Related]
[Next] [New Search]
